ATC 2022

Anatomisch-therapeutisch-chemische Klassifikation Wirkstoffe

L01FFPD-1/PDL-1 (Programmed Cell Death-1-Rezeptor/Programmed Cell Death-Ligand-1)-Inhibitoren

L01FF01NivolumabDDD: 17 mg P

L01FF02PembrolizumabDDD: 9,5 mg P

L01FF03DurvalumabDDD: 50 mg P

L01FF04AvelumabDDD: 57 mg P

L01FF05AtezolizumabDDD: 57 mg P

L01FF06CemiplimabDDD: 17 mg P

L01FF07DostarlimabDDD: 24 mg P

L01FF08Prolgolimab

L01FF09Tislelizumab

L01FF10Retifanlimab